Latest:

Fat Pitch Financials

Special situation stocks and value investing

Stock Quote

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ultragenyx Pharmaceu (NQ: RARE )

38.29 -0.78 (-2.00%)
Streaming Delayed Price Updated: 11:20 AM EDT, Mar 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ultragenyx Pharmaceu

< Previous 1 2 3 4 Next >
What 4 Analyst Ratings Have To Say About Ultragenyx Pharmaceutical
Analysts have provided the following ratings for Ultragenyx Pharmaceutical (NASDAQ:RARE) within the last quarter: 
Via Benzinga
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Ultragenyx Pharmaceutical's Earnings Outlook
Ultragenyx Pharmaceutical (NASDAQ:RARE) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
What 4 Analyst Ratings Have To Say About Ultragenyx Pharmaceutical
Within the last quarter, Ultragenyx Pharmaceutical (NASDAQ:RARE) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish... 
Via Benzinga
Earnings Scheduled For February 10, 2022
Companies Reporting Before The Bell • Canada Goose Hldgs (NYSE:GOOS) is projected to report quarterly earnings at $1.46 per share on revenue of $584.49 million. 
Via Benzinga
Earnings Scheduled For November 2, 2021
Companies Reporting Before The Bell • Thomson Reuters (NYSE:TRI) is expected to report quarterly earnings at $0.48 per share on revenue of $1.86 billion. •... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 16, 2022
Upgrades Bernstein upgraded the previous rating for Stryker Corp (NYSE:SYK) from Market Perform to Outperform. For the fourth quarter, Stryker had an EPS of $2.71, compared to... 
Via Benzinga
Where Ultragenyx Pharmaceutical Stands With Analysts
Ultragenyx Pharmaceutical (NASDAQ:RARE) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish... 
Via Benzinga
Ultragenyx Pharmaceutical: Q4 Earnings Insights
Ultragenyx Pharmaceutical (NASDAQ:RARE) reported its Q4 earnings results on Thursday, February 10, 2022 at 04:05 PM. Here's what investors need to know about the announcement. 
Via Benzinga
The Daily Biotech Pulse: AstraZeneca Q4 Gets COVID Boost, Seagen Plunges On Earnings, Adcom Test Awaits Lilly
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, IPOs And More
Biotech stocks managed to close the week ending Feb. 4 with gains. Stocks recovered along with the broader markets early in the week, but came under pressure midweek amid negative reaction to some big... 
Via Benzinga
Ultragenyx Pharmaceutical inc (RARE) Q3 2021 Earnings Call Transcript
RARE earnings call for the period ending October 2, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus SAB Spikes On Analyst Action SAB Biotherapeutics, Inc. (NASDAQ: SABS) shares... 
Via Benzinga
Exposures COVID-19
Stocks That Hit 52-Week Lows On Wednesday
During Wednesday's morning trading, 400 companies set new 52-week lows. 52-Week Low Highlights: Intuitive Surgical (NASDAQ:ISRG) was the largest company by... 
Via Benzinga
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
What 4 Analyst Ratings Have To Say About Ultragenyx Pharmaceutical
Over the past 3 months, 4 analysts have published their opinion on Ultragenyx Pharmaceutical (NASDAQ: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 30, 2021
Upgrades For Cabot Oil & Gas Corp (NYSE:COG),... 
Via Benzinga
Ultragenyx Resumes Dosing Antisense Trial In Rare Neurogenetic Disorder
The FDA has removed the clinical hold on GeneTx Biotherapeutics LLC and Ultragenyx Pharmaceutical Inc's (NASDAQ: RARE) GTX-102 trial for... 
Via Benzinga
Exposures Product Safety
Return on Capital Employed Insights for Ultragenyx Pharmaceutical
After pulling data from Benzinga Pro it seems like during Q2, Ultragenyx Pharmaceutical (NASDAQ:RARE) posted sales of $86.97 million. Earnings were up 22.33%, but Ultragenyx... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 19, 2021
Upgrades According to DA Davidson, the prior rating for PaySign Inc (NASDAQ: 
Via Benzinga
Return on Capital Employed Overview: Ultragenyx Pharmaceutical
After pulling data from Benzinga Pro it seems like during Q2, Ultragenyx Pharmaceutical (NASDAQ:RARE) posted sales of $86.97 million. Earnings were up 22.33%, but Ultragenyx... 
Via Benzinga
Ultragenyx Pharmaceutical inc (RARE) Q2 2021 Earnings Call Transcript
RARE earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Ultragenyx Pharmaceutical: Q2 Earnings Insights
Shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) moved higher in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were down... 
Via Benzinga
Ultragenyx Pharmaceuticals Analyst Turns Bullish: What Investors Need To Know
A BofA Securities analyst is turning bullish on shares of Ultragenyx Pharmaceuticals (NASDAQ: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 29, 2021
Upgrades For Nutrien Ltd (NYSE: 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Cerevel Therapeutics Hldg (NASDAQ:CERE) shares moved upwards by 42.0% to $17.85 during Tuesday's pre-market session. The company's market cap stands at $2.... 
Via Benzinga
Earnings Scheduled For August 2, 2021
Companies Reporting Before The Bell • HSBC Holdings (NYSE:HSBC) is estimated to report earnings for its second quarter. • Addex Therapeutics (NASDAQ:ADXN) is... 
Via Benzinga
GeneTx Bio-Ultragenyx's Angelman Syndrome Study To Start Enrollment In Canada
GeneTx Biotherapeutics LLC and Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) have received clearance from Health Canada to begin enrolling in the Phase 1/... 
Via Benzinga
CNS Pharmaceuticals Commences Patient Enrollment in Potentially Pivotal Study of Berubicin
CNS Pharmaceuticals today announced open enrollment for its potentially pivotal study evaluating the efficacy and safety of Berubicin in the treatment of recurrent GBM. 
Via Talk Markets
Ultragenyx's Gene Therapies For Genetic Metabolic Disorders Show Longer-Term Durable Responses
Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) has announced longer-term data from the Glycogen Storage Disease Type Ia (GSDIa) and Ornithine Transcarbamylase (... 
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.